<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ASeries_B</id>
	<title>Definition:Series B - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ASeries_B"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Series_B&amp;action=history"/>
	<updated>2026-05-02T20:15:14Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Series_B&amp;diff=19702&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Series_B&amp;diff=19702&amp;oldid=prev"/>
		<updated>2026-03-17T06:19:30Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;💰 &amp;#039;&amp;#039;&amp;#039;Series B&amp;#039;&amp;#039;&amp;#039; is a venture capital financing round that, within the [[Definition:Insurtech | insurtech]] industry, typically represents the stage at which a startup has validated its core product — whether an [[Definition:Underwriting | underwriting]] platform, a [[Definition:Claims management | claims automation]] tool, or a [[Definition:Distribution | distribution]] technology — and is raising capital to scale operations, expand into new markets, or deepen its carrier and [[Definition:Broker | broker]] partnerships. In the broader startup ecosystem, Series B sits between the product-market-fit stage of [[Definition:Series A | Series A]] and the pre-IPO growth stage of [[Definition:Series C | Series C]], but in insurance the round carries particular significance because scaling in a regulated, relationship-driven industry demands substantial investment in [[Definition:Regulatory compliance | compliance]] infrastructure, licensing, and trust-building with established market participants.&lt;br /&gt;
&lt;br /&gt;
⚙️ A Series B round for an insurtech company generally involves institutional venture capital firms — often joined by strategic investors such as [[Definition:Insurance carrier | insurance carriers]], [[Definition:Reinsurance | reinsurers]], or insurance-focused private equity funds — investing in exchange for [[Definition:Preferred stock | preferred equity]] with negotiated governance and liquidation preferences. Round sizes in insurtech have varied widely depending on the business model: a [[Definition:Managing general agent (MGA) | full-stack MGA]] seeking to build its own [[Definition:Loss reserves | loss reserves]] or secure [[Definition:Capacity | capacity]] commitments may require significantly more capital than a pure software-as-a-service platform selling tools to incumbents. The due diligence process at Series B often scrutinizes insurance-specific metrics — [[Definition:Loss ratio | loss ratios]], [[Definition:Gross written premium (GWP) | gross written premium]] growth, [[Definition:Combined ratio | combined ratios]] for risk-bearing insurtechs, or net revenue retention for technology vendors — alongside traditional software metrics like recurring revenue and customer acquisition cost. Strategic investors at this stage frequently bring more than capital: a reinsurer&amp;#039;s participation, for example, may signal future [[Definition:Capacity | capacity]] support, while a carrier investor may offer distribution access.&lt;br /&gt;
&lt;br /&gt;
📌 The Series B stage often determines whether an insurtech company can achieve the scale necessary to become a durable participant in the insurance value chain or remains a niche experiment. Insurance is an industry where trust, regulatory standing, and long-term track records matter enormously — and Series B capital is what typically funds the transition from promising newcomer to credible counterparty. Companies that successfully navigate this round often use the proceeds to obtain additional [[Definition:Insurance license | licenses]] across jurisdictions, build out [[Definition:Actuarial science | actuarial]] and [[Definition:Compliance | compliance]] teams, and invest in the data infrastructure required for sophisticated [[Definition:Risk modeling | risk modeling]]. The round also tends to set the valuation trajectory and investor expectations that shape the company&amp;#039;s path toward later-stage funding, strategic acquisition, or public listing.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Series A]]&lt;br /&gt;
* [[Definition:Series C]]&lt;br /&gt;
* [[Definition:Insurtech]]&lt;br /&gt;
* [[Definition:Venture capital]]&lt;br /&gt;
* [[Definition:Managing general agent (MGA)]]&lt;br /&gt;
* [[Definition:Gross written premium (GWP)]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>